Richard de Bodo is lead trial counsel in high-stakes, cutting-edge patent and trade secret cases for many of the world’s leading pharmaceutical, life sciences, and technology companies.
Rich has an outstanding track record litigating and trying Hatch-Waxman cases and cases relating to biologic drugs, biosimilars, biotechnology, and medical devices. He has won significant victories in federal and state courts, arbitrations, the International Trade Commission (ITC), the US Patent Office, and other forums for companies seeking to protect US and international markets for their products or seeking to launch new products and overcome barriers to entry. Rich has experience counseling companies seeking to launch biosimilars in the US under the Biologics Price Competition and Innovation Act (BPCIA) and representing them in litigation, negotiations, and US Patent Office proceedings.
Rich has consistently been rated as one of the best intellectual property and life sciences lawyers in the U.S. According to Chambers USA, “Clients are impressed by [Rich’s] brilliant mind and unmatched strategic skills.” Chambers quotes one of Rich’s clients that, “When the stakes are high, [Rich] is the only person I’d go to. [He] gets the job done in a measured and calm manner.” Another client stated: “[Rich] is the person you need when you’re faced with highly complicated IP legal matters that involve many variables.”
Rich is a thought leader in the intellectual property and life sciences fields, and regularly lectures and provides commentary on developments in the law. Rich has taught trial advocacy and litigation strategy at the National Institute of Trial Advocacy, the Hastings College of Advocacy, and numerous continuing education programs. Before practicing law, Rich served as a judicial clerk in the US Court of Appeals and the US District Court.